In tumor cells, FGFR inhibits the JAK/STAT signaling pathway activated by T cell‐produced interferon gamma and then reduces the expression of its target genes, namely, beta‐2 microglobulin (B2M), C‐X‐C motif chemokine ligand 10 (CXCL10), and programmed death‐ligand 1 (PD‐L1), thereby mediating immune escape.60 Here, SOAT1 is linked to neoplasm.